Top 5 Stock Market Gainers: VCIG, ITOS, APLS, CTNT, RCUS

WISCONSIN (CoinChapter.com) — The major Wall Street indexes increased Wednesday as Nvidia stock surged on expectations of another positive forecast from the chip maker, which would rekindle an artificial intelligence-driven rally in megacap growth firms.

Here are the five best stock market gainers:

VCI Global Ltd. (NASDAQ: VCIG)

VCI Global Ltd. (NASDAQ: VCIG) has announced a strategic collaboration with Microsoft Azure, which heralds a new era of advancements in the tech landscape. Through its fully owned subsidiary, V Galactech Sdn Bhd, VCI Global is integrating its business solutions with Microsoft Azure’s OpenAI platform. Shares were up a whopping 73.94% on the news today.

iTeos Therapeutics Inc. (NASDAQ: ITOS)

In an unexpected move, Roche unintentionally released positive interim trial data on its lung cancer drug, causing iTeos Therapeutics Inc. (NASDAQ: ITOS) stock to experience a significant increase. This inadvertent disclosure of promising trial results has sparked renewed interest in the biotechnology sector, particularly in iTeos Therapeutics.

Investors will closely monitor further developments around Roche’s lung cancer drug and its potential implications for iTeos Therapeutics’ future growth.

Apellis Pharmaceuticals Inc. (NASDAQ: APLS)

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) announced that it had discovered internal structural variations in the 19-gauge filter needle included with certain Syfovre (pegcetacoplan) injection kits. This discovery was made during an investigation into real-world safety events related to Syfovre, a treatment for geographic atrophy secondary to age-related macular degeneration.

The drug is administered via intravitreal injection to the affected eye, and the filter needle is used to withdraw the drug from its vial.

While a clear causal connection between the needle’s structural variations and rare adverse events has not been established, this issue has triggered a surge in Apellis Pharmaceuticals’ vigilance against potential infections, which also received shareholders’ support with a nearly 30% stock price increase.

Cheetah Net Supply Chain Service Inc. (NASDAQ: CTNT)

In a recent announcement two days ago, Cheetah Net Supply Chain Services Inc. (NASDAQ: CTNT) released its unaudited first-half results for 2023.

According to preliminary data, the company sold 175 luxury vehicles, with 69% of these sales made directly to PRC-based parallel import dealers and the remaining units to US exporters for sale into the PRC.

The company’s gross profit saw a substantial rise of approximately 35%, amounting to an estimated $2.4 million, pushing the gross profit margin to 10.7%. Compared with 5.3% for the same period last year, this significant growth is attributed to higher average selling prices.

Arcus Biosciences Inc. (NYSE: RCUS)

Arcus Biosciences (NYSE: RCUS), a clinical-stage global biopharmaceutical company, has announced that its management team will participate in several upcoming investor conferences in September; the news sent shares up 27.33% today.

The firm develops differentiated molecules and combination therapies for cancer patients; they leverage these conferences to engage with industry partners, patients, and physicians worldwide.